Gene Therapy

Collaborations advance sickle cell program

Published in Blood Weekly, July 31st, 2003

NaPro BioTherapeutics, Inc., (NPRO) has entered into research collaborations with the Children's Hospital of Philadelphia and Jefferson Medical College of Thomas Jefferson University, Philadelphia, for the development of NaPro's gene editing therapy for patients suffering from sickle cell disease.

NaPro's technique for approaching sickle cell disease is to make the single base pair correction in hematopoietic stem/progenitor cells ex vivo and then reinfuse the patients with their own corrected cells.

"We are very excited to collaborate with NaPro. Their unique approach is an intriguing development in addressing this disease at the genetic level,"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry